Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Rheumatology
•
Myositis
•
Rituximab
•
Lupus Anticoagulant
Would you consider adding rituximab to a patient with SLE (lupus anticoagulant positive but no history of thrombotic events) and organizing pneumonia (on azathioprine, prednisone, and hydroxychloroquine) who now also has polymyositis?
Related Questions
How long can you treat dermatomyositis with IVIG?
What is your approach to maintenance treatment in a patient with Sjogren's who received rituximab for mononeuritis multiplex?
Is the efficacy and dose same for subcutaneous vs intravenous IVIGs being used for dermatomyositis?
Do you prefer to taper rituximab by extending the interval between doses or decreasing the actual dose administered for RA patients who have achieved longstanding remission?
Is there a reason to repeat HMGCR antibody level for monitoring disease activity once documented positive in patients with IMNM?
Would you avoid combining JAK inhibitors with IVIG given the risk of thromboembolism?
Do you use MTX along with Rituximab in patients with early NSIP on HRCT in patient with active RA and polymyositis (PL7+)?
How do you go about switching from one DMARD to another In patients with dermatomyositis that remains active?
What is your approach to dosing and duration of rituximab for refractory lupus nephritis not responsive to cyclophosphamide or mycophenolate?
What is your approach to elevated CK in patients without clinical or serologic evidence of immune mediated myopathy?